Published 2022
| Version v1
Publication
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
- Creators
- Lupo-Stanghellini, Maria Teresa
- Di Cosimo, Serena
- Costantini, Massimo
- Monti, Sara
- Mantegazza, Renato
- Mantovani, Alberto
- Salvarani, Carlo
- Zinzani, Pier Luigi
- Inglese, Matilde
- Ciceri, Fabio
- Apolone, Giovanni
- Ciliberto, Gennaro
- Baldanti, Fausto
- Morrone, Aldo
- Sinno, Valentina
- Locatelli, Franco
- Notari, Stefania
- Turola, Elena
- Giannarelli, Diana
- Silvestris, Nicola
- Others:
- Lupo-Stanghellini, Maria Teresa
- Di Cosimo, Serena
- Costantini, Massimo
- Monti, Sara
- Mantegazza, Renato
- Mantovani, Alberto
- Salvarani, Carlo
- Zinzani, Pier Luigi
- Inglese, Matilde
- Ciceri, Fabio
- Apolone, Giovanni
- Ciliberto, Gennaro
- Baldanti, Fausto
- Morrone, Aldo
- Sinno, Valentina
- Locatelli, Franco
- Notari, Stefania
- Turola, Elena
- Giannarelli, Diana
- Silvestris, Nicola
Description
Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine adverse events and disease worsening was one of the reasons for vaccine hesitancy. Herein, we report the safety profile of the prospective, multicenter, national VAX4FRAIL study (NCT04848493) to evaluate vaccines in a large trans-disease cohort of patients with solid or hematological malignancies and neurological and rheumatological diseases.
Additional details
- URL
- https://hdl.handle.net/11567/1103817
- URN
- urn:oai:iris.unige.it:11567/1103817
- Origin repository
- UNIGE